The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for diabetes have become the focal point of attention due to the burgeoning diabetic population size, with diabetes affecting middle age groups and children across all income groups globally.
Some of the major drivers and opportunities for growth of this market include drug combinations of several agents such as sitagliptin and metformin and other drug combinations that are in different stages of clinical and pipeline development. Increase in the prevalence of diabetes and new product launches by major pharmaceutical companies re some of the key drivers for growth in this market. In 2015, BoehringerIngelheim GmbH launched two new drugs (Synjardy&Glyxambi)for treatment of diabetes mellitus type II.
Some of the key opportunities for the antidiabetics include a strong pipeline for antidiabetics and entry of new players in the market, for instance, Novo Nordisk’s diabetes drug’s Tresiba, and Ryzodeg received FDA approval in September 2015. Moreover, BoehringerIngelheim GmbH has a strong pipeline for anti-diabetic drugs, such as Linagliptin which is a dipeptidyl peptidase (DPP) 4 inhibitor) for patients suffering from diabetes mellitus type II and high cardiovascular risk.
Access Report Details at: https://www.themarketreports.com/report/global-anti-diabetic-drugs-market-research-report
The global Anti-Diabetic Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Anti-Diabetic Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Anti-Diabetic Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
Key companies profiled in Anti-Diabetic Drugs Market report are Astra Zeneca, BoehringerIngelheim, Eli Lilly, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Sanofi, Teva Pharmaceutical Industriesand more in term of company basic information, Product Introduction, Application, Specification, Production, Revenue, Price and Gross Margin (2014-2019), etc.
Purchase this Premium Report at: https://www.themarketreports.com/report/buy-now/1424369
Table of Content
1 Anti-Diabetic Drugs Market Overview
2 Global Anti-Diabetic Drugs Market Competition by Manufacturers
3 Global Anti-Diabetic Drugs Production Market Share by Regions
4 Global Anti-Diabetic Drugs Consumption by Regions
5 Global Anti-Diabetic Drugs Production, Revenue, Price Trend by Type
6 Global Anti-Diabetic Drugs Market Analysis by Applications
7 Company Profiles and Key Figures in Anti-Diabetic Drugs Business
8 Anti-Diabetic Drugs Manufacturing Cost Analysis
9 Marketing Channel, Distributors and Customers
10 Market Dynamics
11 Global Anti-Diabetic Drugs Market Forecast
12 Research Findings and Conclusion
13 Methodology and Data Source